Back to Search
Start Over
Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
- Source :
-
Cellular immunology [Cell Immunol] 2004 Feb; Vol. 227 (2), pp. 93-102. - Publication Year :
- 2004
-
Abstract
- Reduced expression of CD62L can identify tumor-specific T cells in lymph nodes draining murine tumors. Here, we examined whether this strategy could isolate tumor-specific T cells from vaccinated patients. Tumor vaccine-draining lymph node (TVDLN) T cells of seven patients were separated into populations with reduced (CD62LLow) or high levels of CD62L (CD62LHigh). Effector T cells generated from CD62LLow cells maintained or enriched the autologous tumor-specific type 1 cytokine response compared to unseparated TVDLN T cells in four of four patients showing tumor-specific cytokine secretion. Interestingly, effector T cells generated from CD62LLow or CD62LHigh TVDLN were polarized towards a dominant type 1 or type 2 cytokine profile, respectively. For CD62LLow T cells the type 1 cytokine profile appeared determined prior to culture. Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy.
- Subjects :
- Carcinoma, Renal Cell therapy
Humans
Immunotherapy, Adoptive
Interferon-gamma biosynthesis
Interleukin-5 biosynthesis
Kidney Neoplasms therapy
Melanoma therapy
Cancer Vaccines immunology
Carcinoma, Renal Cell immunology
Kidney Neoplasms immunology
L-Selectin analysis
Lymph Nodes immunology
Melanoma immunology
T-Lymphocytes immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0008-8749
- Volume :
- 227
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Cellular immunology
- Publication Type :
- Academic Journal
- Accession number :
- 15135291
- Full Text :
- https://doi.org/10.1016/j.cellimm.2004.01.006